Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Bellamy

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
American Journal of Clinical Pathology|October 1, 1996
Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsiesL M Rimsza, E E Vela, Y M Frutiger, et al.
British Journal of Cancer|June 1, 1991
Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell lineC W Taylor, W S Dalton, P R Parrish, et al.
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Leukemia Research|December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Francis J Giles, William T Bellamy, Zeev Estrov, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 15, 2018
Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adultsS O Ali, X Q Yu, G J Robbie, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
American Journal of Clinical Pathology|October 1, 1996
Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsiesL M Rimsza, E E Vela, Y M Frutiger, et al.
British Journal of Cancer|June 1, 1991
Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell lineC W Taylor, W S Dalton, P R Parrish, et al.
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Leukemia Research|December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Francis J Giles, William T Bellamy, Zeev Estrov, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 15, 2018
Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adultsS O Ali, X Q Yu, G J Robbie, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
Pageof 4